Q4 26 EPS
$1.66
BEAT +0.86%
Est. $1.65
Q4 26 Revenue
$1.95B
BEAT +1.73%
Est. $1.91B
Full Year 2026 Results
FY 26 EPS
$5.53
BEAT +0.17%
Est. $5.52
FY 26 Revenue
$6.72B
BEAT +0.53%
Est. $6.68B
Did CLX Beat Earnings? Q4 2026 Results
Clorox posted a modest beat across both top and bottom lines in Q4 FY2026, but the headline numbers told only part of a complicated story. The consumer products company reported adjusted EPS of $1.66, edging past the $1.65 consensus by 0.86%, while r… Read more Clorox posted a modest beat across both top and bottom lines in Q4 FY2026, but the headline numbers told only part of a complicated story. The consumer products company reported adjusted EPS of $1.66, edging past the $1.65 consensus by 0.86%, while revenue of $1.95 billion cleared estimates by 1.73%, even as sales slipped 2.0% year over year. The most significant drag on results was the company lapping an ERP-related shipment surge from the prior-year quarter, a comparison that alone accounted for roughly $0.90 of the 42% decline in adjusted EPS and nearly 13.5 percentage points of the organic sales drop. Gross margin contracted 520 basis points to 41.3%, further pressured by inventory step-up charges tied to the April 2026 GOJO Industries acquisition. Analysts had flagged ahead of the print that a profit outlook reset was possible, and indeed Clorox guided FY2027 adjusted EPS to a range of $5.70 to $6.00, representing 3% to 8% growth, alongside net sales growth of 13% to 14%, with the GOJO deal contributing roughly 9.5 points of that lift.
Key Takeaways
- • GOJO acquisition added approximately 10 points to Q4 net sales growth
- • Lapping ERP-related incremental shipments from prior year reduced organic sales by about 13.5 points in Q4
- • Gross margin declined 520 basis points to 41.3% due to lower volume, GOJO inventory step-up, higher commodity costs, and higher manufacturing and logistics costs
- • Cost savings partially offset gross margin headwinds
- • International segment grew 4% with organic sales up 1% and segment adjusted EBIT up 17%
CLX Forward Guidance & Outlook
For fiscal year 2027, Clorox expects net sales growth of 13% to 14%, including approximately 9.5 points of benefit from the GOJO acquisition. Organic sales are expected to increase about 3.5% to 4.5%, including more than 3.5 points of benefit from lapping the ERP-related drawdown. Gross margin is expected to be about 42%, reflecting higher-than-normal inflationary headwinds and negative mix, partially offset by cost savings. Selling and administrative expenses are expected to be about 16% of net sales. Advertising and sales promotion spending is expected to be about 10% of net sales. The effective tax rate is expected to be about 23%. Diluted EPS is expected between $5.41 and $5.71, an increase of 12% to 19% year over year. Adjusted EPS is expected between $5.70 and $6.00, representing growth of 3% to 8%. These growth rates include the benefit of lapping the ERP inventory drawdown from the prior year.
CLX YoY Financials
Q4 2026 vs Q4 2025, source: SEC Filings
CLX Revenue by Segment
With YoY comparisons, source: SEC Filings
“Our fourth-quarter results were in line with our expectations and reflect disciplined execution in a dynamic environment. Throughout fiscal year 2026, we strengthened our business despite continued consumer and macroeconomic pressures. We expanded our portfolio through the acquisition of GOJO Industries, completed our U.S. ERP implementation, a foundational modernization of the systems and processes that underpin every aspect of our operations, while advancing our digital capabilities. Together, these actions have strengthened our foundation and position us well to navigate a challenging operating environment as we work to return to organic sales growth. We exited the year with improved execution, a stronger innovation pipeline and a clear plan to deliver superior value across our portfolio, better meeting evolving consumer needs and driving long-term growth.”
— Linda Rendle, Q4 2026 Earnings Press Release
CLX Earnings Trends
CLX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
CLX EPS Trend
Earnings per share: estimate vs actual
CLX Revenue Trend
Quarterly revenue: estimate vs actual
CLX Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q4 26 BEAT FY | $1.65 | $1.66 | +0.86% | $1.95B | +1.73% |
| FY Full Year | $5.52 | $5.53 | +0.17% | $6.72B | +0.53% |
| Q3 26 BEAT | $1.50 | $1.64 | +9.33% | $1.67B | +0.10% |
| Q2 26 MISS | $1.43 | $1.39 | -2.80% | $1.67B | +2.19% |
| Q1 26 BEAT | $0.78 | $0.85 | +8.97% | $1.43B | +2.21% |
| Q4 25 BEAT FY | $2.21 | $2.87 | +29.86% | $1.99B | +3.05% |
| FY Full Year | $7.06 | $7.72 | +9.38% | $7.10B | +0.83% |
| Q3 25 MISS | $1.56 | $1.45 | -7.05% | $1.67B | -2.86% |